Immune checkpoint inhibitors or targeted therapy by mismatch repair status in endometrial cancer: a meta-analysis.
메타분석
1/5 보강
PICO 자동 추출 (휴리스틱, conf 3/4)
유사 논문P · Population 대상 환자/모집단
환자: advanced or recurrent endometrial cancer (EC) via network meta-analysis
I · Intervention 중재 / 시술
prior chemotherapy, the lenvatinib plus pembrolizumab strategy shows promise
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
[CONCLUSIONS] ICIs offered advantages for the dMMR population, whereas selinexor could provide survival benefits for the pMMR population. For pMMR patients who have received prior chemotherapy, the lenvatinib plus pembrolizumab strategy shows promise.
[OBJECTIVE] This study evaluated the benefits of immune checkpoint inhibitors (ICIs) and/or targeted therapies in mismatch repair-deficient (dMMR) and mismatch repair-proficient (pMMR) patients with a
- 연구 설계 meta-analysis
APA
Tang Y, Chen Y, et al. (2025). Immune checkpoint inhibitors or targeted therapy by mismatch repair status in endometrial cancer: a meta-analysis.. Future science OA, 11(1), 2541517. https://doi.org/10.1080/20565623.2025.2541517
MLA
Tang Y, et al.. "Immune checkpoint inhibitors or targeted therapy by mismatch repair status in endometrial cancer: a meta-analysis.." Future science OA, vol. 11, no. 1, 2025, pp. 2541517.
PMID
40804781
Abstract
[OBJECTIVE] This study evaluated the benefits of immune checkpoint inhibitors (ICIs) and/or targeted therapies in mismatch repair-deficient (dMMR) and mismatch repair-proficient (pMMR) patients with advanced or recurrent endometrial cancer (EC) via network meta-analysis.
[METHODS] English databases were searched from inception through January 2025. Randomized controlled trials (RCTs) assessing the efficacy and safety of related therapies for patients with EC stratified by MMR status were included. The main evaluation indicators included progression-free survival (PFS), overall survival (OS), the objective response rate (ORR), and severe adverse events (SAEs).
[RESULTS] Ten studies were included in the analysis. The results indicated that in the dMMR population, ICIs provide superior survival benefits. Among these, Dostarlimab combined with carboplatin and paclitaxel (CP) had the highest PFS and OS rates. For the pMMR population, Selinexor + CP offers significant benefits over CP alone, although OS outcome data are limited. In pMMR patients with prior chemotherapy, the lenvatinib + pembrolizumab strategy may provide additional PFS benefits relative to chemotherapy treatment.
[CONCLUSIONS] ICIs offered advantages for the dMMR population, whereas selinexor could provide survival benefits for the pMMR population. For pMMR patients who have received prior chemotherapy, the lenvatinib plus pembrolizumab strategy shows promise.
[METHODS] English databases were searched from inception through January 2025. Randomized controlled trials (RCTs) assessing the efficacy and safety of related therapies for patients with EC stratified by MMR status were included. The main evaluation indicators included progression-free survival (PFS), overall survival (OS), the objective response rate (ORR), and severe adverse events (SAEs).
[RESULTS] Ten studies were included in the analysis. The results indicated that in the dMMR population, ICIs provide superior survival benefits. Among these, Dostarlimab combined with carboplatin and paclitaxel (CP) had the highest PFS and OS rates. For the pMMR population, Selinexor + CP offers significant benefits over CP alone, although OS outcome data are limited. In pMMR patients with prior chemotherapy, the lenvatinib + pembrolizumab strategy may provide additional PFS benefits relative to chemotherapy treatment.
[CONCLUSIONS] ICIs offered advantages for the dMMR population, whereas selinexor could provide survival benefits for the pMMR population. For pMMR patients who have received prior chemotherapy, the lenvatinib plus pembrolizumab strategy shows promise.
같은 제1저자의 인용 많은 논문 (5)
- Advances in intravesical therapy for non-muscle-invasive bladder cancer.
- Long-term survival with PD-1/PD-L1 inhibitors plus platinum-based chemotherapy versus chemotherapy alone in locally advanced or metastatic pulmonary lymphoepithelioma-like carcinoma: updated follow-up analysis.
- Alterations in dynamic regional homogeneity and functional connectivity in lung cancer patients with bone metastasis pain.
- Examined lymph node counts ≤6 are correlated with an unfavorable prognosis in stage IA NSCLC patients following sublobar resection: a retrospective study employing propensity score matching analysis.
- Identification of Potential Therapeutic Targets for Xihuang Pill in Breast Cancer: A Mendelian Randomization and Experimental Study.